Bert Lopansri, MD
Infectious Disease · Salt Lake City, UTNPI 1538261292
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,500 of the $19,855 with a category attached, or 88.1%. BD accounts for 89.8% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2021 at $17,780 and has fallen 99.2% since, to $139 in 2025. Among infectious disease clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 14 payments — averaging $1418.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BD$18K
- Qiagen, LLC$2K
- Opgen, Inc.$221
- Beckman Coulter, Inc.$135
- Cormedix Inc.$76
- T2 Biosystems, Inc.$62
- plus $37 from 3 others
Across 4 payments — averaging $41,823 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Opgen, Inc.$88K
- Cepheid$79K
What the payments were for
- Consulting fees$1,5008%
- Speaking & faculty fees$17,50088%
- Travel & lodging$160%
- Food & beverage$8244%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| BD | 5 | $17,824 |
| Qiagen, LLC | 1 | $1,500 |
| Opgen, Inc. | 1 | $221 |
| Beckman Coulter, Inc. | 2 | $135 |
| Cormedix Inc. | 1 | $76 |
| T2 Biosystems, Inc. | 1 | $62 |
| AbbVie | 1 | $19 |
| Insmed, Inc. | 1 | $16 |
| Intuitive Surgical | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MICROSCAN WALKAWAY$119
How this compares
$19,855 in reported general payments places this provider in the 95th percentile of 44 infectious disease providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $50,843 |
| TivicayDolutegravir Sodium | 20 | $44,518 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $27,753 |
| IsentressRaltegravir Potassium | 12 | $23,228 |
| Darunavir | 13 | $19,157 |
| Ritonavir | 13 | $1,082 |
| Cephalexin | 22 | $845 |
| Minocycline Hcl | 16 | $433 |
| CeftriaxoneCeftriaxone Sodium | 14 | $256 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $132 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Salt Lake City
- William TettelbachSalt Lake City$82K
- Kimberly HansonSalt Lake City$22K
- David ClassenSalt Lake City$14K
- Andrew SkinnerSalt Lake City$10K
- Adam SpivakSalt Lake City$5K
- Marquam OliverSalt Lake City$4K
- Joel TrachtenbergSalt Lake City$2K
- Emily Sydnor SpivakSalt Lake City$1K
- Sankar SwaminathanSalt Lake City$800
- Patricia Ruggeri-WeigelSalt Lake City$737
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.